Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall
Evotec SE announced the nomination of a preclinical development candidate in its dermatology collaboration with Almirall S.A., achieving this milestone within two years. The program aims to develop novel treatments for immune-mediated inflammatory skin diseases.
Evotec SE and Almirall S.A. have nominated a small molecule preclinical development candidate for immune-mediated inflammatory skin diseases. The joint team achieved this in two years, outperforming standard industry timelines. Evotec's AI/ML-driven R&D capabilities and Almirall's dermatology expertise drove the program. The collaboration began in May 2022 and included an upfront payment and potential milestones of up to €230 million per program. Evotec will support the program toward IND submission through its INDiGO platform. The companies aim to develop novel treatments for severe skin diseases.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.